Sirolimus, an mTOR inhibitor, targets this pathway and early research has demonstrated its effectiveness in the treatment for some vascular malformations (1, 14, 17, 18), implying that the endothelium in AVM is not “quiescent,” as previously assumed. The gene discussed is MTOR; the disease is vascular malformation.